The shorter OS and/or PFS associated with the RNA expression of ZEB1 and SNAI1 by CTCs may indicate a more aggressive and potentially docetaxel resistant phenotype being present in the primary or metastatic tumour sites, which may promote disease progression in mHSPC patients. Here, ZEB1 is linked to metastatic neoplasm.